Celgene Corporation and LLS-partner Epizyme Announce Deal That Will Help Advance Therapy for Mixed Lineage Leukemia Patients

Thanks to funding from The Leukemia & Lymphoma Society (LLS), Epizyme has been advancing DOT1L, a targeted histone methyltransferase inhibitor (HMTi) as a personalized therapeutic for patients...R…
Read the full story: Biomarker Commons